证券代码：688132 证券简称：邦彦技术 公告编号：2025-028 邦彦技术股份有限公司 第三届监事会第二十四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 邦彦技术股份有限公司(以下简称"公司")第三届监事会第二十四次会议于 2025 年 4 月 28 日采用通讯表决的方式召开。本次会议通知及相关材料已于 2025 年 4 月 25 日以邮件的方式送达公司全体监事。会议应出席监事 3 人，实际出席 监事 3 人，会议由监事会主席许巧丰主持，本次会议的召开符合有关法律、法规 和《公司章程》的规定，会议决议合法、有效。 （一）审议通过《关于公司 2025 年第一季度报告的议案》 监事会认为：公司 2025 年第一季度报告的编制和审议程序符合相关法律法 规及《公司章程》等内部规章制度的规定，其内容与格式符合中国证监会和上海 证券交易所的各项规定，公允地反映了公司的财务状况和经营成果等事项。该报 告披露的信息真实、准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。 表决结果：同意 3 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥27,705,846.88, a decrease of 78.38% compared to ¥128,131,366.18 in the same period last year[4] - The net profit attributable to shareholders was -¥27,205,560.94, representing a decline of 177.02% from ¥35,322,518.87 year-on-year[4] - The basic and diluted earnings per share were both -¥0.18, a decrease of 175.00% from ¥0.24 in the same period last year[4] - Net profit for Q1 2025 was a loss of CNY 27,466,990.32, compared to a profit of CNY 35,176,842.33 in Q1 2024, indicating a significant decline[18] Research and Development - The total R&D investment reached ¥19,214,241.16, an increase of 57.72% compared to ¥12,182,573.10 in the previous year[5] - R&D expenses accounted for 69.35% of operating revenue, up by 59.84 percentage points from 9.51%[5] - Research and development expenses for Q1 2025 were CNY 19,214,241.16, an increase of 74.5% from CNY 11,027,517.32 in Q1 2024[17] - The company established a strategic cooperation with The Chinese University of Hong Kong (Shenzhen) for postdoctoral talent, enhancing its future technological innovation capabilities[13] Cash Flow and Liquidity - The net cash flow from operating activities was -¥36,626,074.09, compared to -¥26,442,386.60 in the same period last year[4] - Cash inflow from operating activities in Q1 2025 was CNY 32,523,519.57, down from CNY 54,629,558.11 in Q1 2024, a decrease of 40.5%[21] - The company's cash and cash equivalents decreased from 228.84 million RMB to 187.02 million RMB, a decline of approximately 18.3%[12] - The ending balance of cash and cash equivalents decreased to $187.02 million from $225.59 million, reflecting a decline of approximately 17.1%[24] - The net cash flow from operating activities was -$36.63 million, compared to -$26.44 million in the previous period, indicating a decline in operational cash generation[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,687,712,577.78, a decrease of 1.62% from ¥1,715,588,496.20 at the end of the previous year[5] - The equity attributable to shareholders was ¥1,432,558,707.94, down 1.84% from ¥1,459,408,530.92 at the end of the previous year[5] - Total liabilities as of the end of the reporting period were CNY 254,496,194.94, slightly down from CNY 255,260,861.00[16] - The company's non-current assets totaled 715.17 million RMB, down from 724.35 million RMB, a decrease of approximately 1.4%[14] Inventory and Borrowings - Inventory increased from 82.97 million RMB to 89.37 million RMB, representing an increase of approximately 7.5%[14] - Short-term borrowings rose significantly from 12.00 million RMB to 27.00 million RMB, an increase of approximately 125%[14] Market and Strategic Initiatives - The significant decline in revenue and profit was primarily influenced by customer delivery and acceptance schedules, leading to a substantial drop in sales[7] - The company reported a total of 1.55 billion RMB in hand orders and production notices, providing strong support for future performance[13] - The company held a grand launch event for its cloud PC products, partnering with industry leaders like AOC Technology and Kirin Technology to expand the cloud PC market[13]

| × | | --- | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 6 | | 第一节 | 股东 | 6 | | 第二节 | 控股股东和实际控制人 | 9 | | 第三节 | 股东会的一般规定 | 10 | | 第四节 | 股东会的召集 | 13 | | 第五节 | 股东会的提案与通知 | 15 | | 第六节 | 股东会的召开 | 16 | | 第七节 | 股东会的表决和决议 | 19 | | 第五章 | 董事和董事会 | 23 | | 第一节 | 董事的一般规定 | 23 | | 第二节 | 董事会 | 27 | | 第三节 | 独立董事 | 31 | | 第四节 | 董事会专门委员会 | 34 | | 第六章 | 高级管理人员 | 36 | | 第七章 | 财务会计制度、利润分配和审计 | 38 | | 第一节 | 财务会计制度及利润分配 | ...

2025 年 4 月 28 日 此外，上述独立董事候选人具有丰富的专业知识，熟悉相关法律、行政法规、规 章与规则，其任职资格、教育背景、工作经历、业务能力符合公司独立董事任职要求。 其中王晶女士是会计专业人士，并具备注册会计师资格、高级会计师职称。 因此，我们同意提名孔东升先生、吴保元先生、王晶女士为第四届董事会独立董 事候选人。并同意提请公司董事会和股东大会予以审议。 邦彦技术股份有限公司 董事会提名委员会 邦彦技术股份有限公司董事会提名委员会 关于第四届董事会独立董事候选人的审查意见 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董事管 理办法》（以下简称"《管理办法》"）《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规以及《邦彦技术股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，邦彦技术股份有限公司（以下简称"公司"）第三届董事会 提名委员会对拟提交公司董事会审议的《关于董事会换届选举暨提名第四届董事会独 立董事候选人的议案》进行了审议，经对独立董事候选人的简历和相关资料进行审查， 发表如下审查意见： 经审查孔东升先生、吴保元先生、王晶女士的个人 ...

邦彦技术股份有限公司 董事会审计委员会工作细则 邦彦技术股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条 为强化邦彦技术股份有限公司（以下简称"公司"）董事会决策功 能，加强公司董事会对管理层有效监督，完善公司治理结构，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《上市公司治理准则》《上市公司独 立董事管理办法》《邦彦技术股份有限公司章程》（以下简称"《公司章程》"） 及其他有关法律、行政法规和规范性文件，公司设董事会审计委员会，并制定本 工作细则。 第二条 审计委员会委员应保证足够的时间和精力履行委员会的工作职责， 勤勉尽责，切实有效地监督公司的外部审计，指导公司内部审计工作，促进公司 建立有效的内部控制并提供真实、准确、完整的财务报告。 第二章 人员组成 第三条 审计委员会由3名董事组成，审计委员会成员应当为不在公司担任 高级管理人员的董事，其中独立董事应当过半数，公司董事会成员中的职工代表 可以成为审计委员会成员。 第四条 审计委员会委员由董事长、1/2以上独立董事或者全体董事的1/3以上 提名，并由董事会选举产生。 第五条 审计委员会设主任委员一名作为委员会召集人，由独立董事中 ...

Financial Performance - The company reported a basic earnings per share of -0.1800 yuan for Q1 2025, a decrease of 175% compared to 0.2400 yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.27 billion yuan, representing a decline of 177.14% from 0.35 billion yuan in Q1 2024 [1] - The operating revenue for Q1 2025 was 0.28 billion yuan, down 78.13% from 1.28 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -1.88%, a significant drop of 182.46% compared to 2.28% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 46.8994 million shares, accounting for 43.22% of the circulating shares, with a slight decrease of 0.10 million shares from the previous period [2] - The largest shareholder, Jinpai Co., Ltd., holds 23.40 million shares, representing 21.57% of the total share capital, with no change [3] - Other notable shareholders include Shenzhen Zhongyan Innovation Investment Partnership and Shenzhen Innovation Investment Group, holding 6.3255 million shares (5.83%) and 2.797 million shares (2.58%) respectively, both unchanged [3] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [4]

证券代码：688132 证券简称：邦彦技术 公告编号：2025-023 2024年12月2日，公司召开第三届董事会第二十四次会议、第三届监事会第 二十二次会议，审议通过了《关于公司本次发行股份及支付现金购买资产并募 集配套资金暨关联交易方案的议案》《关于公司本次发行股份及支付现金购买 资产并募集配套资金暨关联交易预案及其摘要的议案》等与本次交易相关的议 案，具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 相关公告。 关于发行股份及支付现金购买资产并募集配套资金 暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本次交易的基本情况 邦彦技术股份有限公司（以下简称"公司"）拟通过发行股份及支付现金的 方式购买深圳星网信通科技股份有限公司100%的股份，同时募集配套资金（以 下简称"本次交易"）。 经公司向上海证券交易所申请，公司股票（股票简称：邦彦技术，证券代 码：688132）自2024年11月25日开市起停牌，具体内容详见公司于2024年11月 25日、2024年11 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [1][19]. Core Views - The company achieved a revenue of 347 million yuan in 2024, representing a year-on-year growth of 91.98%. However, it reported a net loss attributable to shareholders of 36.61 million yuan, an improvement from a loss of 52.25 million yuan in the previous year [1][4]. - The growth in the ship communication business is robust, with revenue reaching 280 million yuan, a staggering increase of 355.47% year-on-year. The company is also expanding into civilian products, leveraging its expertise in domestic self-control and information security [8]. - The company plans to acquire 100% of Xingwang Xintong, which is expected to enhance business synergy and accelerate growth. The acquisition includes a performance commitment of at least 180 million yuan in net profit over three years [8]. Financial Summary - For 2024, the total revenue is projected at 347 million yuan, with a growth rate of 92.0%. The net profit attributable to shareholders is expected to improve to a profit of 74 million yuan by 2025, with corresponding EPS of 0.48 yuan [4][8]. - The company’s total assets are estimated to grow from 1.716 billion yuan in 2024 to 2.325 billion yuan by 2027, indicating a strong upward trend in financial health [9]. - The company’s market capitalization is currently 2.918 billion yuan, with a circulating market value of 2.080 billion yuan [5].

Regulatory Developments - The National Medical Products Administration reported four cases of illegal online sales of medical devices, emphasizing a "zero tolerance" regulatory attitude to ensure safety in medical device usage [2] - Companies involved include Jiangyin Tianyu Medical Device Co., Yiwu Shenghe Medical Device Co., Shanghai Yile Warehouse Medical Device Co., and Hefei Baohua Design Studio, all of which failed to comply with regulatory requirements [2] Industry Advancements - Hangzhou is accelerating the development of medical artificial intelligence applications, aiming to establish a national AI (medical) application pilot base and create intelligent medical entities focused on various health management areas [3] - The city plans to build digital health innovation laboratories to advance key technologies in medical AI [3] Company Announcements - Leksin Medical received a medical device registration certificate for its wrist-type electronic blood pressure monitor from the Guangdong Provincial Drug Administration [5] - David Medical's wholly-owned subsidiary, Ningbo Yongxing Medical Instruments Co., obtained a medical device registration certificate for a linear cutting stapler used in various surgical procedures [6] - Warner Pharmaceuticals announced the approval of its drug registration certificate for the injection of methoxamine hydrochloride, used for treating acute hypotension during spinal anesthesia [7] Financial Reports - Guobang Pharmaceutical reported a revenue of 1.44 billion yuan for Q1 2025, a year-on-year increase of 7.57%, with a net profit of 215 million yuan, up 8.17% [9] - Johnson & Johnson's Q1 sales reached 21.89 billion dollars, with an annual sales forecast of 91 to 91.8 billion dollars and adjusted earnings per share projected between 10.50 and 10.70 dollars [10] Market Movements - In Hong Kong, InnoCare's stock surged by 130% on its first trading day [12] - Darentang announced plans to transfer a 12% stake in China-US Tianjin Schering Pharmaceutical Co., with estimated investment income of approximately 1.54 billion yuan from the transaction [13] - Nanjing Noling Biotechnology completed a C-round financing of several hundred million yuan, led by Dingxin Capital [14] Collaborative Initiatives - Berry Genomics' subsidiary signed a project cooperation framework agreement with Beijing Children's Hospital to promote clinical transformation and commercialization of research outcomes related to newborn screening technologies [16] - Bangyan Technology plans to officially launch its AI Agent product this year, aimed at assisting digital transformation in the healthcare sector [17] Personnel Changes - Bell Bio's financial officer, Zhao Baozhen, resigned for personal reasons but will continue to serve as the board secretary [19]

Summary of Conference Call Company and Industry - The conference call discusses a company involved in the development of AI Agents and cloud PC products, indicating a focus on digital transformation and innovation in the technology sector. Key Points and Arguments 1. **AI Agent Development**: The company is integrating AI Agents with cloud PC products, aiming for significant breakthroughs in digital employee solutions, which are expected to enhance operational efficiency for businesses [1][3][4]. 2. **Market Recovery**: There are signs of recovery in the military sector, which the company anticipates will benefit from increased military spending and demand for its products [2][18]. 3. **Product Differentiation**: The cloud PC product is positioned as a solution that overcomes the limitations of traditional virtual desktop infrastructure (VDI) by providing a more efficient and secure computing environment [5][6][7]. 4. **Market Size and Potential**: The commercial PC market is estimated to be around 200 billion yuan, with the company targeting a significant share, especially in sectors requiring high security and performance [15][16]. 5. **Business Model**: The AI Agent product will be available for both B2B and B2C markets, with revenue generated through project-based fees for custom solutions and usage-based fees for standard services [11][22]. 6. **Competitive Landscape**: The company acknowledges competition from major players in the digital employee space but believes it has unique advantages in specific applications and customer segments [10][12]. 7. **Regulatory Compliance**: The cloud PC product is expected to receive national security certifications, which will open up procurement opportunities in sensitive sectors such as government and military [16][19]. 8. **Future Outlook**: The company is optimistic about its growth trajectory, with expectations of significant revenue from both military and commercial sectors, projecting a total revenue of around 600 million yuan for the year [19][33]. Other Important Content - **Technological Integration**: The AI Agent is designed to enhance traditional products by adding intelligent features, which will improve operational capabilities in various sectors, including military applications [24][30]. - **Customer Engagement**: The company is actively engaging with potential clients, including government and enterprise sectors, to facilitate product trials and feedback, which is crucial for contract conversions [26][27]. - **Investment Opportunities**: The company encourages investors to explore its innovative solutions and potential market impact, highlighting the importance of understanding the evolving technology landscape [34]. This summary encapsulates the main themes and insights from the conference call, providing a comprehensive overview of the company's strategic direction and market positioning.